# Inhibitor Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Inhibitor Therapeutics, Inc.). ## Overview Inhibitor Therapeutics, Inc. is a U.S.-based pharmaceutical development company focused on repurposing approved drugs into patent-protected cancer therapies. Its current lead effort centers on itraconazole-based treatments for basal cell carcinoma nevus syndrome (BCCNS), with additional programs referenced for prostate and lung cancers. ## Products & services • Itraconazole-based cancer therapies • BCCNS / basal cell carcinoma treatment program • Prostate cancer development program • Lung cancer development program • Novel itraconazole formulation development • FDA pre-IND and NDA development support - **Lead oncology repurposing program** (55%) — Development of itraconazole-based therapies for BCCNS and related basal cell carcinoma indications. - **Additional oncology indications** (20%) — Early-stage development work for prostate cancer and lung cancer using the same repurposing platform. - **Formulation and delivery development** (15%) — Novel itraconazole formulation work intended to support pharmacokinetic studies and regulatory filings. - **Intellectual property licensing** (10%) — Exclusive patent rights and know-how licensed from Johns Hopkins University and related IP assets. - Itraconazole-based cancer therapies - BCCNS / basal cell carcinoma treatment program - Prostate cancer development program - Lung cancer development program - Novel itraconazole formulation development - FDA pre-IND and NDA development support ## Customers The company does not sell commercial products today; its end customers are patients and physicians in oncology and rare-disease settings if development succeeds. Near term, its direct counterparties are regulators, clinical collaborators, and research partners that support the IND/NDA pathway. The commercial opportunity is concentrated in patients with BCCNS and other cancers where itraconazole-based treatment could address unmet need. - **BCCNS / basal cell carcinoma patients** (primary) — Patients targeted by the lead itraconazole program for BCCNS-related tumors and basal cell carcinoma. - **Prostate and lung cancer patients** (secondary) — Future patient populations for the company's patent-protected oncology expansion programs. - **Regulatory agencies** (primary) — FDA reviewers and divisions that determine whether the company can advance to IND, trial, and NDA stages. - **Clinical and formulation partners** (secondary) — External experts and Avior Bio supporting formulation, PK work, and regulatory preparation. - Patients with BCCNS and basal cell carcinoma if approved - Oncologists and dermatology specialists treating rare tumors - FDA and other regulators reviewing clinical and NDA filings - Clinical research partners supporting trials and PK studies - Potential future prescribers in prostate and lung cancer ## Geography The company is headquartered in the United States and its development and regulatory work is centered there. Its patent rights are described as worldwide, but the current clinical and FDA pathway is U.S.-focused, making domestic regulatory execution the key geographic driver. Any eventual commercialization could expand beyond the U.S., but no operating revenue geography is disclosed. - Headquartered in the United States - Clinical and FDA development work is U.S.-based - Exclusive patent rights are worldwide - No country-level revenue disclosure available - Commercial exposure depends on U.S. regulatory progress ## Strategy The core strategy is to repurpose an already approved active ingredient into patent-protected oncology therapies, reducing scientific risk versus de novo drug discovery. Management is prioritizing the BCCNS program, FDA interaction, and formulation work needed to determine whether additional clinical trials are required before an NDA submission. The company also intends to license or acquire additional pre-clinical and clinical-stage assets that fit the same repurposing model. - **Resolve FDA development path for BCCNS** (short-term) — Regulatory clarity determines whether the company needs more trials before NDA submission. - **Complete novel itraconazole formulation work** (short-term) — The formulation supports PK comparison and may strengthen the regulatory package. - **Expand the pipeline through licensing or acquisition** (medium-term) — Additional assets could diversify risk beyond the lead BCCNS program. - Advance the BCCNS program through FDA pre-IND and NDA planning - Use itraconazole repurposing to reduce development risk and cost - Complete novel formulation and PK work to support filings - Leverage Johns Hopkins patent rights for exclusivity - Evaluate additional oncology and non-cancer opportunities ## Risks The company is highly dependent on FDA review outcomes, timing, and interpretation of its development package, which can materially delay or prevent commercialization. As a pre-revenue biotech, it also faces financing risk, clinical development uncertainty, and dependence on third-party partners for formulation and study execution. Broader sector risks include regulatory shutdowns, trial failure, patent challenges, and the possibility that repurposed itraconazole does not demonstrate sufficient efficacy or safety in the targeted indications. - **FDA review and regulatory timing risk** [high] — The business depends on timely FDA feedback and approval of the development path. - **Need for additional clinical trials** [high] — If the FDA requires more data, development costs and timelines could increase materially. - **Financing and dilution risk** [high] — The company may need to raise capital to fund development and future opportunities. - **Program concentration risk** [medium] — Value is concentrated in a small number of repurposed oncology programs. - **Regulatory shutdown / agency disruption risk** [medium] — Government shutdowns can delay FDA and SEC processing and access to capital markets. - FDA delays could slow or block IND/NDA progress - Additional clinical trials may be required before approval - Cash needs may force dilutive capital raises - Lead program concentration creates single-asset risk - Third-party formulation and study execution risk ## Accounting As a development-stage biotech, the most important accounting judgments are around research and development spending, capital raising, and the valuation of any acquired or licensed intangible assets. The company also notes that management estimates and assumptions are used in preparing the financial statements, which is especially relevant for pre-commercial entities with limited operating history. Investors should watch for how future licensing arrangements, clinical costs, and any impairment of IP or other assets affect reported results. - **Research and development expense recognition** — Affects quarterly burn rate and comparability across periods - **Intangible asset valuation and impairment** — Could create non-cash charges if expected value declines - **Management estimates and assumptions** — Can affect accruals, provisions, and asset valuation - **Future licensing and collaboration accounting** — Could change reported revenue and deferred income balances - R&D expense timing affects reported losses and burn rate - License and patent rights may require impairment testing - Estimates and assumptions drive pre-commercial accounting - Future financing could create dilution and issuance costs - No revenue recognition complexity yet, but future licensing may add it --- *Last updated: 2026-04-28T20:17:26.554617+00:00*